BEAUTYFARM MED (02373) announced that its board has resolved to allocate up to HK$1.2 billion over the next three years to enhance shareholder value through the following methods: (i) declaring annual dividends under the company’s current dividend policy (as disclosed in its March 26, 2025, dividend policy update, the company intends to distribute no less than 50% of its annual net profit attributable to shareholders as ordinary dividends for the next three fiscal years, barring exceptional circumstances); or (ii) repurchasing shares in the open market under the general mandate approved at its June 27, 2025, annual general meeting and any subsequent authorizations granted by shareholders after the existing buyback mandate expires. The company plans to fund these initiatives through internal resources and expects no material adverse impact on its working capital. Shareholders and potential investors should note that the company is authorized to repurchase up to 23,579,556 shares under the existing buyback mandate, with 605,500 shares already repurchased as of the announcement date.